Advertisement

Topics

Nonmedical Biosimilar Switch Results Surprise Investigators

13:24 EDT 30 Jun 2017 | Medscape

When the Danish government mandated a switch to the infliximab biosimilar, researchers had the perfect opportunity to study the effect on patients with rheumatologic inflammatory disease.
Medscape Medical News

Original Article: Nonmedical Biosimilar Switch Results Surprise Investigators

NEXT ARTICLE

More From BioPortfolio on "Nonmedical Biosimilar Switch Results Surprise Investigators"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...